Will Coherus BioSciences (CHRS) Stock Bounce Back?

Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here. Economic slowdown, inflation, ongoing Russia-Ukraine war, and Federal Reserve actions provided uncertainty in the market. Investors reacted negatively to these issues; thus, the equity market declined considerably in the second quarter. The small-cap funds represented by the Russell 2000 Growth Index declined significantly in the quarter. Investing in small-cap companies involves more risk compared to other investments. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Carillon Tower Advisers discussed stocks like Coherus BioSciences, Inc. (NASDAQ:CHRS) in the second quarter 2022 investor letter. Headquartered in Redwood City, California, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a biopharmaceutical company. On October 6, 2022, Coherus BioSciences, Inc. (NASDAQ:CHRS) stock closed at $9.73 per share. One-month return of Coherus BioSciences, Inc. (NASDAQ:CHRS) was -7.51% and its shares lost 44.72% of their value over the last 52 weeks. Coherus BioSciences, Inc. (NASDAQ:CHRS) has a market capitalization of $756.26 million.

Here is what Carillon Tower Advisers specifically said about Coherus BioSciences, Inc. (NASDAQ:CHRS) in its Q2 2022 investor letter:

“Coherus BioSciences, Inc. (NASDAQ:CHRS) produces biosimilar therapies. The stock struggled in a market where biotech stocks underperformed. The company continues to work toward approval of several important new biosimilars.”

Coherus BioSciences, Inc. (NASDAQ:CHRS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held Coherus BioSciences, Inc. (NASDAQ:CHRS) at the end of the second quarter which was 18 in the previous quarter.

We discussed Coherus BioSciences, Inc. (NASDAQ:CHRS) in another article and shared the list of biotechnology stocks to buy according to Kerr Neilson’s Platinum Asset Management. In addition, please check out our hedge fund investor letters Q2 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.